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ABSTRACT

Compositions and methods for treating a Yersinia pestis (I’.
pestis) infection are provided. Compositions and methods of
for inducing an immune response in a subject are provided.
Composition can include a YadC polypeptide.

10 Claims, 5 Drawing Sheets
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COMPOSITIONS AND METHODS FOR
TREATING YERSINIA PESTIS INFECTION

This Summary describes several embodiments of the pres
ently-disclosed subject matter, and in many cases lists varia
tions and permutations of these embodiments. This Summary
is merely exemplary of the numerous and varied embodi

RELATED APPLICATIONS

ments. Mention of one or more representative features of a

This application claims priority from US. Provisional
Application Ser. No. 60/828,895 ?led Oct. 10, 2006, the
entire disclosure of Which is incorporated herein by this ref

given embodiment is likeWise exemplary. Such an embodi
ment can typically exist With or Without the feature(s) men

tioned; likeWise, those features can be applied to other

embodiments of the presently-disclosed subject matter,

erence.

Whether listed in this Summary or not. To avoid excessive
GOVERNMENT INTEREST

repetition, this Summary does not list or suggest all possible
combinations of such features.

Subject matter described herein Was made With US. Gov
ernment support under Grant Number AI48491, IUF4

The presently-disclosed subject matter includes composi
tions and methods for treating a I’ersinia peslis (I’. peslis)
infection (or plague resulting from such an infection). Com
positions and methods of the presently-disclosed subject mat

AI057175, and 5K30HL004163-05 aWarded by the National
Institute of Allergy and Infectious Diseases of the National
Institute of Health. The United States government has certain
rights in the subject matter.

ter can be used for inducing an immune response in a subject.
In some embodiments, compositions include an isolated

polypeptide molecule comprising a sequence at least 80%,
TECHNICAL FIELD

The presently-disclosed subject matter relates to composi
tions and methods for preventing and/or treating plague,
including compositions and methods for preventing and/or
treating infection by I’ersinia peslis.

20

85%, 90%, or 95% identical to SEQ ID NO: 1, or a functional

fragment thereof. In some embodiments, the isolated
polypeptide molecule comprises a sequence at least 80%,
85%, 90%, or 95% identical to SEQ ID NO: 3. In some

embodiments, the isolated polypeptide molecule comprises
25

INTRODUCTION AND GENERAL
CONSIDERATIONS

the sequence of SEQ ID NO: 3.
In some embodiments, compositions include an isolated
polypeptide molecule comprising a sequence at least 80%,
85%, 90%, or 95% identical to an amino acid sequence

including residues 137-345 of SEQ ID NO: 1. In some

I’ersinia peslis is a highly virulent extracellular pathogen,

30

embodiments, compositions include an isolated polypeptide

35

molecule comprising a sequence at least 80%, 85%, 90%, or
95% identical to an amino acid sequence including residues
137-345 of SEQ ID NO: 1. In some embodiments, composi
tions include an isolated polypeptide molecule comprising a
sequence at least 80%, 85%, 90%, or 95% identical to an

Which causes lethal infection in humans and other animals. I’.

peslis infection causes plague, including bubonic, pneu
monic, and septicemic plague. The bacterium poses an omi
nous threat as an agent of bioterrorism. It is highly infectious
and contagious by aerosol and can kill in as little as tWo days
after exposure.

amino acid sequence including residues 32-345 of SEQ ID

I’. peslis can be categorized into sub-types, including: Anti
gua, Medievalis, and Orientalis. I’. peslis pathogenicity can be
blocked by antibodies to tWo protein antigens, the capsule
subunit Cafl (also knoWn as F1 antigen, or Fraction 1 anti

NO: 1.
In some embodiments, compositions include an isolated
40

gen), and a surface protein called V antigen (also knoWn as

LcrV). In this regard, compositions including the F1 antigen
and the V antigen have been studied for use in treating and

preventing I’. peslis infection. Although such compositions
have been shoWn to offer modest protection, against some
strains of I’. peslis, there are many virulent strains of I’. peslis.

Examples of such strains include, for example, strain KIM of
the Mediaevalis sub-type, and strain C092 of the Orientalis
sub-type. Additionally, modi?cations to I’. peslis antigens can
be made Without destroying virulence. For example, the V-an

45

NO: 1.
In some embodiments, compositions include an isolated
polypeptide molecule comprising a sequence at least about
80%, 85%, 90%, or 95% identical to an amino acid sequence
50

tigen is variable, such that knoWn compositions containing
the V-antigen may not be fully protective against certain
modi?ed strains. Furthermore, the F1 antigen is not required
for virulence in pneumonic plague, and its gene is easily
deleted, posing the potential of a WeaponiZed Fl-lacking I’.

ofSEQ ID NO: 1, Whereinup to about 5, 10, 15, 20, 25, 30, 50,
125, or 150 amino acids are truncated from the N-terminus of

SEQ ID NO: 1. In some embodiments, the isolated polypep

tide molecule comprises at least about 200, 210, 225, 235,
245, 255, 265, 275, 285, 295, 300, 325, 350 or 375 amino
55

peslis against Which knoWn compositions containing F1 anti

acids of SEQ ID NO: 1.
In some embodiments, compositions include an isolated
polypeptide molecule comprising a sequence at least about
80%, 85%, 90%, or 95% identical to an amino acid sequence

gen are not effective.

Accordingly, there remains a need in the art for composi

tions and methods for preventing and/or treating various
types and strains of I’. peslis infection.

polypeptide molecule comprising an amino acid sequence
including residues 32-345 of SEQ ID NO: 1. In some embodi
ments, compositions include an isolated polypeptide mol
ecule comprising an amino acid sequence including residues
32-409 of SEQ ID NO: 1. In some embodiments, composi
tions include an isolated polypeptide molecule comprising an
amino acid sequence including residues 32-409 of SEQ ID

60

of SEQ ID NO: 1, Wherein up to about 10, 50, 75, 100, 150,
175, 200, 225, 250, 275, 300, 325, 350, or 400 amino acids are
truncated from the C-terminus of SEQ ID NO: 1. In some

embodiments, the isolated polypeptide molecule comprises
at least about 200, 210, 225, 235, 245, 255, 265, 275, 285,

SUMMARY
The presently-disclosed subject matter meets some or all of
the above-identi?ed needs, as Will become evident to those of

ordinary skill in the art after a study of information provided
in this document.

295, 300, 325,350 or 375 amino acids of SEQ ID NO: 1.
65

In some embodiments, compositions comprise anpolypep
tide molecule encoded by a nucleotide sequence at least about
80, 85, 90, or 95% identical to SEQ ID NO: 2, or a subse

US 7,815,911 B1
3

4

quence thereof. The encoded polypeptide has improved

sequence ofSEQ ID NO: 1With up to about 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 15, 20, or 25 conservative amino acid substitutions,

immune response activity relative to, or has all or some of the

immune response activity of, a polypeptide encoded by a

or a functional fragment thereof. In some embodiments,

nucleotide sequence of SEQ ID NO: 2. In some embodi

methods include introducing into the subject a composition
comprising an isolated polypeptide molecule comprising the
sequence ofSEQ ID NO: 3 With up to about 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 15, 20, or 25 conservative amino acid substitutions,

ments, the polypeptide molecule is encoded by a subsequence
of the nucleotide sequence of SEQ ID NO: 2, Wherein up to

about 15, 30, 45, 60, 75, 90, 150, 375, or 450 nucleotide
residues are truncated from the 5' terminus of SEQ ID NO: 2.
In some embodiments, the polypeptide molecule is encoded

or a functional fragment thereof.

by a subsequence of the nucleotide sequence of SEQ ID NO:

BRIEF DESCRIPTION OF THE DRAWINGS

2, Wherein up to about 30, 150,225,300, 450, 525, 600, 675,
750, 825, 900, 975, 1050, or 1200 nucleotide residues are
truncated from the 3' terminus of SEQ ID NO: 2.

FIG. 1 is a schematic representation of the predicted struc
ture of YadB and YadC.
FIG. 2 is a graph depicting the results of a study Wherein

In some embodiments, compositions include a conserva

tively-substituted variant of the polypeptide molecule of SEQ

immuniZed mice Were intravenously challenged With 1’. pes

ID NO: 1, or functional fragments thereof. In some embodi

Zis. There Was no protection for those immunized With buffer

ments, compositions include a conservatively-substituted
variant of the polypeptide molecule of SEQ ID NO: 3, or

alone (Buffer), full protection for HT-LcrV-immuniZed mice

functional fragments thereof.

niZed mice (YadC).

In some embodiments, the polypeptide molecule includes
the amino acid sequence of SEQ ID NO: 1, or a subsequence

(LcrV), and partial protection for GST-YadCl37_4O9-immu
20

FIG. 3 is a graph depicting the results of a study Wherein
immuniZed mice Were intranasally challenged With 1’. peslis.
87% of GST-YadCl37_4O9-immuniZed mice survived pneu
monic plague, as compared to the GST-immuniZed control
group (0 surviving mice) and the HT-LcrV-immuniZed group,

25

Where 50% survived.
FIGS. 4A-4D are a series of bar graphs depicting periph

thereof, With up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or
25 conservative amino acid substitutions. In some embodi

ments, the polypeptide molecule includes the amino acid
sequence of SEQ ID NO: 3, or a subsequence thereof, With up

to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 conservative
amino acid substitutions. In some embodiments, the conser
vative amino acid substitutions are at or betWeen residues

eral macrophage (PBM) cytokine response. GST-YadCl37_
409 leads to increased IL-1, IL-6 and TNF-ot production When

346-622 of the YadC polypeptide of SEQ ID NO: 1, or a

subsequence thereof. In some embodiments, the polypeptide
molecule includes the amino acid sequence of SEQ ID NO: 1,
or a subsequence thereof, With up to about 1, 2, 3, 4, or 5

compared to HT-LcrV.
30

BRIEF DESCRIPTION OF THE SEQUENCE
LISTING

conservative amino acid substitutions are at or betWeen resi

dues 32-345 of the YadC polypeptide of SEQ ID NO: 1, or a

subsequence thereof.

35

In some embodiments, compositions induce an immune

SEQ ID NO: 2 is a nucleotide sequence encoding the YadC

response in a subject against Fl-positive and Fl-negative
strains of I’. peslis. In some embodiments, compositions
induce an immune response in a subject against Fl-negative
strains of I’. peslis. In some embodiments, the subject is in

SEQ ID NO: 1 is an amino acid sequence for a YadC

polypeptide;
polypeptide of SEQ ID NO: 1;
SEQ ID NO: 3 is an amino acid sequence for an exemplary

40

fragment of the YadC polypeptide of SEQ ID NO: 1; and

need of treatment for a I’. peslis infection. In some embodi

DESCRIPTION OF EXEMPLARY
EMBODIMENTS

ments, the subject is susceptible to I’. peslis infection.
In some embodiments, methods include administering to a

subject a composition including a YadC polypeptide, as
The details of one or more embodiments of the presently
disclosed subject matter are set forth in this document. Modi
?cations to embodiments described in this document, and

described herein. The composition can be administered in an
amount su?icient to induce an immune response in the sub

ject. The presently-disclosed subject matter includes methods
for treating a Yersinia peslis (1’. peslis) infection and/or treat
ing a plague resulting from such an infection, including
administering to the subject an effective amount of a compo
sition including a YadC polypeptide, as described herein. In
some embodiments, methods include introducing into a sub

other embodiments, Will be evident to those of ordinary skill
in the art after a study of the information provided in this
50

standing and no unnecessary limitations are to be understood

ject a composition comprising an isolated polypeptide mol
ecule comprising an amino acid sequence of SEQ ID NO: 1,
or a functional fragment thereof. In some embodiments,

therefrom. In case of con?ict, the speci?cation of this docu
55

disclosed subject matter belongs. Although any methods,
60

methods include introducing into the subject a composition
comprising an isolated polypeptide molecule comprising the

compositions, and materials similar or equivalent to those
described herein can be used in the practice or testing of the

presently-disclosed subject matter, representative methods,

functional fragment thereof. In some embodiments, methods
include introducing into a subject a composition comprising
a sequence at least 80, 85, 90, or 95% identical to SEQ ID NO:
3, or a functional fragment thereof. In some embodiments,

ment, including de?nitions, Will control.
Unless de?ned otherWise, all technical and scienti?c terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to Which the presently

methods include introducing into a subject a composition
comprising an isolated polypeptide molecule comprising an
amino acid sequence of SEQ ID NO: 3, or a functional frag
ment thereof. In some embodiments, methods include intro
ducing into a subject a composition comprising a sequence at
least 80, 85, 90, or 95% identical to SEQ ID NO: 1, or a

document. The information provided in this document, and
particularly the speci?c details of the described exemplary
embodiments, is provided primarily for cleamess of under

compositions, and materials are noW described.

FolloWing long-standing patent laW convention, the terms
65

“a”, “an”, and “the” refer to “one or more” When used in this

application, including the claims. Thus, for example, refer
ence to “a cell” includes a plurality of such cells, and so forth.

US 7,815,911 B1
5

6

Unless otherwise indicated, all numbers expressing quan
tities of ingredients, properties such as reaction conditions,

in a subject; and/or ameliorating or relieving the symptoms
associated With a I’. peslis infection and/or plague occurring

and so forth used in the speci?cation and claims are to be

in a subject.
In some embodiments, the compositions and methods of

understood as being modi?ed in all instances by the term
“about”. Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this speci?cation and claims
are approximations that can vary depending upon the desired

the presently-disclosed subject matter canbe used for treating
an Fl-positive (131+) or an Fl-negative (Fl') 1’. peslis strain.
In some embodiments, the compositions and methods can be
used for treating a I’. peslis C092 strain. In some embodi

properties sought to be obtained by the presently-disclosed

ments, the compositions and methods can be used for treating
an F1“ 1’. peslis strain. In some embodiments, the composi

subject matter.
As used herein, the term “about,” When referring to a value
or to an amount of mass, Weight, time, volume, concentration

tions and methods can be used for treating an Fl'I’. peslis

C092 strain. Embodiments of the compositions and methods
can be used for treating any I’. peslis strain having a yadC

or percentage is meant to encompass variations of in some

embodiments 120%, in some embodiments 110%, in some
embodiments 15%, in some embodiments 11%, in some
embodiments 10.5%, and in some embodiments 10.1% from
the speci?ed amount, as such variations are appropriate to

YadC polypeptide. (YadC is also knoWn as YP01388 of I’.
peslis C092). In some embodiments, compositions include at

perform the disclosed method.
The presently-disclosed subject matter includes composi

least tWo isolatedYadC polypeptides. In some embodiments,
compositions can include a YadC polypeptide, and at least

tions and methods for inducing an immune response in a

gene.
In some embodiments, compositions include an isolated

20

includes antibodies, such as humaniZed monoclonal antibod

ies, that recogniZe epitopes of YadC, and active antibody
fragments. As used herein, the term “immune response”
refers to a humoral and/or cellular immune response, in a

25

subject, to an introduction of a composition described herein,
Which response interferes With or inhibits the virulence, activ

antibodies, T-cells, macrophages, B-cells, dendritic cells, etc.

W095/24475; W02004/019980; W02005/023205; and
The terms “polypeptide,
30

protein,” and “peptide” refer to

a polymer of the 20 protein amino acids, or amino acid ana

logs, regardless of its siZe or function. Although “protein” is
often used in reference to relatively large polypeptides, and
“peptide” is often used in reference to small polypeptides,

These responses can be measured routinely, as Will be under

stood by those of ordinary skill in the art. As used herein, an
immune response activity refers to the ability of a compound
to elicit an immune response.

the folloWing references, each of Which is incorporated herein
by this reference: U.S. Pat. Nos. 3,137,629; 5,985,285; 6,638,
510; 6,706,522; and 6,964,770; and Us. Patent Publication
Nos: 2004/0151727; 2005/0136075; 2005/0220797; and
2005/0232940; and PCT Publication Nos: W095/18231;
W02005/120561.

ity, spread, and/or groWth of a Yersinia peslis (1’. peslis).
Examples of immune responses include the stimulation of

one additional compounds for treating I’. peslis infection, for
example, one or more of the compounds identi?ed in one of

subject. The presently-disclosed subject matter further

35

As used herein, the term “subject” refers to both human and
animal subjects. Thus, veterinary therapeutic uses are pro
vided in accordance With the presently-disclosed subject mat
ter. As such, the presently disclosed subject matter provides

usage of these terms in the art overlaps and varies. Therefore,
the terms “protein,” “polypeptide,” and “peptide” are used

interchangeably herein, unless otherWise noted. Exemplary
polypeptides include gene products, naturally occurring pro
teins, homologs, orthologs, paralogs, fragments and other
equivalents, variants, and analogs of the foregoing. The term

for the treatment of mammals such as humans, as Well as 40 “isolated”, When used in the context of an isolated polypep

those mammals of importance due to being endangered, such

tide, is a polypeptide that, by the hand of man, exists apart

as Siberian tigers; of economic importance, such as animals
raised on farms for consumption by humans; and/ or animals
of social importance to humans, such as animals kept as pets

from its native environment and is therefore not a product of
nature. An isolated polypeptide can exist in a puri?ed form or

or in ZOOS. Examples of such animals include but are not

can exist in a non-native environment.
45

As used herein, the term “fragment” refers to a sequence
that comprises a subset of another sequence. When used in the
context of an amino acid sequence, the terms “fragment” and
“subsequence” are used interchangeably. A fragment or sub

50

residues that is less than that found in a reference polypeptide,
and can include, but is not limited to, domains, features,
repeats, etc. Also, it is understood that a fragment or subse
quence of an amino acid sequence need not comprise the

55

repeat, etc. A fragment can also be a “functional fragment,” in
Which the fragment retains some or all of the activity of the
reference polypeptide as described herein. For example, a
functional fragment of a reference polypeptide that is a I’.
peslis antigen can retain some or all of the immune response

60

activity of the reference polypeptide.

limited to: carnivores such as cats and dogs; sWine, including

pigs, hogs, and Wild boars; ruminants and/ or ungulates such
as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels;
and horses. Also provided is the treatment of birds, including
the treatment of those kinds of birds that are endangered
and/or kept in Zoos, as Well as foWl, and more particularly

sequence of an amino acid sequence can be any number of

domesticated foWl, i.e., poultry, such as turkeys, chickens,
ducks, geese, guinea foWl, and the like, as they are also of
economic importance to humans. Thus, also provided is the
treatment of livestock, including, but not limited to, domes

entirety of the amino acid sequence of the domain, feature,

ticated sWine, ruminants, ungulates, horses (including race
horses), poultry, and the like.
The compositions and methods of the presently-disclosed
subject matter can be used for treating a Yersinia peslis (1’.

peslis) infection and/or treating a plague resulting from such
an infection. As used herein, the terms “treatment” and “treat
ing” relate to any treatment of a I’. peslis, including but not

limited to prophylactic treatment (i.e., pre-infection), and
therapeutic treatment (i.e., post-infection). The terms “treat
ment” or “treating” include: preventing the development of a

Ypeslis infection and/or plague occurring in a subject; reduc
ing the severity of a Ypeslis infection and/ or plague occurring

65

The terms “variant” and “modi?ed,” When used to describe
polypeptide refer to a polypeptide that is different from a
reference polypeptide as a result of an intentional manipula
tion of the amino acid sequence of the polypeptide, or the
nucleic acid sequence encoding the amino acid sequence of
the polypeptide. For example, a modi?ed polypeptide or
polypeptide variant can contain at least one amino acid sub

US 7,815,911 B1
7
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stitution relative to a reference polypeptide. In some embodi

ment is set forth in SEQ ID NO: 3. For another example, in

ments, a modi?ed polypeptide can include one or more addi

some embodiments, the polypeptide molecule comprises the
amino acid sequence including amino acid residues 137-345
of YadC. For another example, in some embodiments, the

tions and/ or deletions or relative to the amino acid sequence

of the reference polypeptide, so long as the modi?edpolypep

polypeptide molecule comprises the amino acid sequence

tide maintains some or all of the activity of the reference
polypeptide as described herein.
The term “conservatively substituted variant” refers to a

including amino acid residues 32-345 of YadC. For another
example, in some embodiments, the polypeptide molecule
comprises the amino acid sequence including amino acid

polypeptide comprising an amino acid sequence that differs

residues 32-409 ofYadC. In some embodiments the polypep

from a reference polypeptide by one or more conservative
amino acid substitution, and maintains some or all of the

tide molecule comprises a fragment of SEQ ID NO: 1,
Wherein up to about 5, 10, 15, 20, 25, 30, 50, 125, or 150

activity of the reference polypeptide as described herein. A
“conservative amino acid substitution” is a substitution of an

amino acids are truncated from the N-terminus of SEQ ID

amino acid residue With a functionally similar residue.
Examples of conservative substitutions include the substitu
tion of one non-polar (hydrophobic) residue such as isoleu
cine, valine, leucine or methionine for another; the substitu
tion of one polar (hydrophilic) residue for another such as

NO: 1 and/or Wherein up to about 10, 50, 75, 100, 150, 175,
200, 225, 250, 275, 300, 325, 350, or 400 amino acids are
truncated from the C-terminus of SEQ ID NO: 1. In some

embodiments, the polypeptide molecule comprises at least

about 200, 210, 225, 235, 245, 255, 265, 275, 285, 295, 300,

betWeen arginine and lysine, betWeen glutamine and aspar
agine, betWeen threonine and serine; the substitution of one
basic residue such as lysine or arginine for another; or the
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substitution of one acidic residue, such as aspartic acid or
glutamic acid for another; or the substitution of one aromatic

residue, such as phenylalanine, tyrosine, or tryptophan for
another. The phrase “conservatively substituted variant” also
includes polypeptides Wherein a residue is replaced With a

25

325, 350 or 375 amino acids of SEQ ID NO: 1.
In some embodiments, the YadC polypeptide is a variant,
such as a conservatively-substituted variant, of a polypeptide
having the amino acid sequence of SEQ ID NO: 1, or a
sub sequence thereof. For example, in some embodiments, the
YadC polypeptide is a conservatively-substituted variant hav
ing the amino acid sequence of SEQ ID NO: 1, or a subse

quence thereof, With up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15,

chemically derivatiZed residue, provided that the resulting

20, or 25 conservative amino acid substitutions. In some

polypeptide maintains some or all of the activity of the refer

embodiments, the YadC polypeptide is a conservatively-sub
stituted variant of a polypeptide having the amino acid

ence polypeptide as described herein.

“Percent identity,” or “percent homology” When used

sequence of SEQ ID NO: 3. In some embodiments, up to

herein to describe to an amino acid sequence, relative to a 30 about 1, 2, 3, 4, or 5 amino acid substitutions are betWeen

reference sequence, can be determined using the formula

amino acid residues 32-345 of the YadC polypeptide of SEQ

described by Karlin andAltschul (Proc. Natl. Acad. Sci. USA

ID NO: 1, or a subsequence thereof. In some embodiments,
the amino acid substitutions are primarily betWeen amino

87: 2264-2268, 1990, modi?ed as in Proc. Natl. Acad. Sci.

USA 90:5873-5877, 1993). Such a formula is incorporated
into the basic local alignment search tool (BLAST) programs
ofAltschul et al. (J. Mol. Biol. 215: 403-410, 1990). To obtain

acid residues 346-622 of the YadC polypeptide of SEQ ID
35

gapped alignments for comparison purposes, Gapped

NO: 1, or a subsequence thereof. In some embodiments, all of
the amino acid substitutions are betWeen amino acid residues
346-622 of the YadC polypeptide of SEQ ID NO: 1, or a

BLAST is utiliZed as described in Altschul, et al. (Nucleic

subsequence thereof. Variants can have improved immune

Acids Res. 25: 3389-3402, 1997). When utiliZing BLAST
and Gapped BLAST programs, the default parameters of the
respective programs (e. g., XBLAST) are used.
In some embodiments of the presently-disclosed subject

response activity relative to, or can maintain some or all of the
40

polypeptide, relative to the polypeptide having the amino acid

matter, a composition for inducing an immune response in a

subject comprises an isolated polypeptide molecule compris
ing an amino acid sequence encoded by a nucleotide
sequence of SEQ ID NO: 2. In some embodiments, the com
position for inducing an immune response in a subject com
prises an isolated polypeptide molecule comprising an amino
acid sequence encoded by a subsequence of the nucleotide
sequence of SEQ ID NO: 2, so long as the encoded polypep
tide has improved immune response activity relative to, or has
all or some of the immune response activity of, a polypeptide
encoded by a nucleotide sequence of SEQ ID NO: 2. In some

45

activity relative to, or maintain some or all of the immune

sequence of SEQ ID NO: 1. In some embodiments, the YadC

polypeptide includes a polypeptide having 80%, 85%, 90%,
50

as the polypeptide has improved immune response activity

activity of, the polypeptide having the amino acid sequence of
55

SEQ ID NO: 1.
In some embodiments of the presently-disclosed subject
matter, the compositions can be provided in a formulation
appropriate for administration to a subject, as Will be under

stood by those of ordinary skill in the art. For example, in

about 30, 150, 225, 300, 450, 525, 600, 675, 750, 825, 900,
60

3' terminus of SEQ ID NO: 2.
In some embodiments, the YadC polypeptide of the com
positions includes a polypeptide having an amino acid

some embodiments, the compositions can be provided in as a
liquid solution or a suspension, suitable for injection. In some
embodiments, solid forms of the compositions that are suit

able for solution in, or suspension in, liquid prior to injection
can be provided. In some embodiments, compositions can be

sequence as set forth in SEQ ID NO: 1, or a functional

fragment thereof. For example, in some embodiments, the
polypeptide molecule comprises the amino acid sequence
including amino acid residues 137-409 of YadC, Which frag

or 95% identity to a polypeptide having the amino acid
sequence of SEQ ID NO: 1, or a subsequence thereof, so long
relative to, or maintain some or all of the immune response

otide sequence ofSEQ ID NO: 2, Wherein up to about 15, 30,
45, 60, 75, 90, 150, 375, or 450 nucleotide residues are trun
cated from the 5' terminus of SEQ ID NO: 2, and/or up to
975, 1050, or 1200 nucleotide residues are truncated from the

sequence of SEQ ID NO: 1, or a subsequence thereof. Such
modi?ed polypeptides can have improved immune response

response activity of, the polypeptide having the amino acid

embodiments, the isolated polypeptide molecule comprises
an amino acid sequence encoded by a fragment of the nucle

immune response activity of the polypeptide having the
amino acid sequence of SEQ ID NO: 1.
In some embodiments, the YadC polypeptide is a modi?ed
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mixed With excipients, such as, for example, Water, saline,
dextrose, glycerol, ethanol, and combinations thereof. In
some embodiments, formulations can include one or more

US 7,815,911 B1
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adjuvants. In some embodiments, the adjuvant is a aluminum
hydroxide, e. g., aluminum hydroxide gel known as ALHY

et al., (1990) Remington's Pharmaceutical Sciences, 18th ed.
Mack Pub. Co., Easton, Pa.; and Speight et al., (1 997) Avery's

DROGEL® (E. M. Sergeant Pulp & Chemical Co. (Clifton,

Drug Treatment: A Guide to the Properties, Choice, Thera
peutic Use and Economic Value ofDrugs in Disease Man

N.J.)). Other suitable adjuvants for use in the practice of the
present subject matter include, but are not limited to polymers

agement, 4th ed. Adis International, Auckland/ Philadelphia.

of acrylic or methacrylic acid, maleic anhydride and alkenyl
derivative polymers, immunostimulating sequences (ISS),

In some embodiments, compositions can further include

additional compounds for treating I’. pestis infection, for

such as oligodeoxyribonucleotide sequences having one or

example, one or more of the compounds identi?ed in one of

more non-methylated CpG units, cation lipids containing a
quaternary ammonium salt, cytokines, and aluminum phos

the folloWing references, each of Which is incorporated herein
by this reference: US. Pat. Nos. 3,137,629; 5,985,285; 6,638,
510; 6,706,522; and 6,964,770; and US. Patent Publication
Nos: 2004/0151727; 2005/0136075; 2005/0220797; and
2005/0232940; and PCT Publication Nos: W095/18231;

phate.
The presently-disclosed subject matter includes methods
for inducing an immune response in a subject, including
administering to a subject a composition including a YadC
polypeptide, as described above. The composition can be

W095/24475; W02004/019980; W02005/023205; and
W02005/120561.

administered in an amount su?icient to induce an immune

The presently-disclosed subject matter is further illustrated

response in the subject. The presently-disclosed subject mat
ter includes methods for treating a Yersinia pestis (1’. pestis)

by the folloWing speci?c but non-limiting examples. The
folloWing examples may include compilations of data that are
representative of data gathered at various times during the

infection and/or treating a plague resulting from such an

infection, including administering to the subject an effective

20

amount that is required Will vary from subject to subject,
depending on the species, age, and general condition of the

EXAMPLES
25

Bacterial strains and plasmids. I’. pestis C099-3015 strains
Were groWn in Heart Infusion Broth (Difco laboratories,

Detroit, Mich.) supplemented With 2.5 mM CaCl2 and 0.2%

subject, the particular carrier or adjuvant being used, mode of

xylose (sHIB) on sHIB agar. E. coli strains Were groWn in

administration, and the like. As such, the effective amount
Will vary based on the particular circumstances, and an appro
priate effective amount can be determined in a particular case

course of development and experimentation related to the

presently-disclosed subject matter.

amount of a composition including a YadC polypeptide, as
described above.
As used herein, the term “effective amount” refers to a
dosage su?icient to elicit an immune response. The exact

30

by one of ordinary skill in the art using only routine experi

Luria-Bertani broth (LB) or on LB-based agar. The bacterial
strains and plasmids used in studies described herein are set
forth in Table 1. Antibiotics Were used at the folloWing con

centrations during genetic constructions: carbenicillin (Cb),
100 ug/ml; kanamycin, 25 ug/ml chloramphenicol, 25 ug/ml.

mentation.

For additional guidance regarding formulation and dose,

Cb Was used at 50 ug/ml for groWth of I’. pestis strains con

see BerkoW et al., (1997) The Merck Manual of Medical
Information, Home ed. Merck Research Laboratories, White
house Station, N.J.; Goodman et al., (2006) Goodman &

taining pCD2Ap. The presence of the pigmentation locus
(Perry 1997) Was con?rmed by the formation of red colonies
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Gilman's the Pharmacological Basis of Therapeutics, 11th
ed. McGraW-Hill Health Professions Division, NeW York;

Ebadi, (1998) CRC Desk Reference ofClinical Pharmacol
ogy. CRC Press, Boca Raton, Fla.; KatZung, (2007) Basic &
Clinical Pharmacology, 10th ed. Lange Medical Books/
McGraW-Hill Medical Pub. Division, NeW York; Remington

on Congo Red agar (Surgalla 1969). The presence of a func
tional Lcr virulence plasmid Was con?rmed by absence of
groWth at 37° C. on sHIB agar containing 20 mM MgCl2 and

20 mM sodium oxalate (Mg0x plates) and by assaying
expression and secretion ofYops during groWth in the de?ned
medium TMH (Straley 1986) With and Without 2.5 mM

CaCl2.
TABLE 1

Bacterial Strains and Plasmids Used in This Study.
Strain or Plasmid

Key Properties

Source or Reference

If pestis
C099-3015
C099-3015.S2

Wildtype strain; subclone of C092; molecular grouping 1.0RI.
C092 Pgm” Lcr’ Aca?, pPst; Fl’ derivative made by allelic

CDC Ft. Collins

Spencer Leigh

exchange into avirulent Lcr’ Fl” I’. pestis C099-3015 obtained
from Scott Bearden (CDC Ft. Collins); entire ca? coding sequence
and 12 upstream bp deleted.
C099-3015.S5

C092 Apgm Lcr” pFra, pPst; conditionally virulent“ Apgm

Scott Bearden

derivative of C099-3015.
C099-3015.S6

Forman 2006

made from C099-3015.S5 by allelic exchange; used as source of

pCD2Ap for electroporation into Lcr’ strains to reconstitute

potential virulence.
C099-3015.S7
C099-3015.S9

C092 Apgm Lcr” Aca?, pPst; Fl’ Apgm attenuated strain made
from C099-3015.S5 by allelic exchange.
C092 Pgm” Lcr” Aca?, pPst; reconstituted Lcr” Fl’ conditionally
virulentl7 strain made by allelic exchange.
E. coli

This Study
This Study
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TABLE 1-continued

Bacterial Strains and Plasmids Used in This Study.

Strain or Plasmid

DH50L

Key Properties

Source or Reference

end-1 hsdR17(rk-mk+) supE44 thi-1 recA1 gyrA (Nalr) relAl

Life Technologies,

A(lacIZYA-argF)U169 deoR (<I>80dlacA (lacZ)M15).

Gaithersburg MD

Plasmids

pKD3
pKD46
pCP20
pHT-V

Template plasmid; cat ?anked by FRT sites; Cm’Ap’
Red recombinase expression plasmid; Apr.
Suicide plasmid With temperature-sensitive replication and
thermally induced expression of FLP recombinase; Ap’Cmr
PCR-ampli?ed lcrV cloned into pProEX-l; expresses full-length

Datsenko 2000
Datsenko 2000
Datsenko 2000
Fields 1999

LcrV With a His6—containing 23-residue N-terminal leader

pGEX—YadC137,4O9

sequence (HT-LcrV).
Sequence encoding amino acids 137-409 ofYadC in pGEX-3X;

Forman 2006

expresses GS T—YadC1374O9.
‘Tull virulence is conditional on intravenous route of infection (Perry 1997).
bFull virulence is conditional on intranasal route ofinfection (Davis 1996).
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Production of the protein capsule F1 Was abolished by

The resultant cellular extracts and supernatant proteins
Were then analyzed by immunoblot for the presence of
secreted LcrV andYopM, as described in Wulff- Strobel 2001,
to determine Whether the type three secretion system Was
fully functional. Several isolated colonies Were then pooled
and stocked.

deleting the caf1 gene. Primers Were used to generate a PCR

fragment containing the FRP site-?anked cat gene from
pKD3 ?anked by caf1 sequence, and caf1 Was deleted by
allelic exchange mediated by the Red and F1p recombinases
as described in Datsenko, 2000. The resulting deletion started
at —12 by upstream of the caf1 translation initiation codon
through the last translated codon. The absence of F1 expres
sion Was veri?ed by immunoblot of 37° C.-groWn yersiniae

Preparation of YadC Polypeptide. The YadC polypeptide

Inc., Flanders, N.J.), and the absence of cat in the ?nal strain

selected for testing in the present study Was a fragment of the
YadC polypeptide of SEQ ID NO: 1. The fragment includes
amino acid residues 137-409 of the amino acid sequence of
SEQ ID NO: 1, Which are set forth in SEQ ID NO: 3. To

Was con?rmed by PCR and by inability to groW on chloram

produce GST-YadCl37_409 (Forrnan 2006), E. coli DHSO. con

phenicol-containing plates.

taining plasmid pGEX-YadCl37_409 Was groWn to an OD620

using the monoclonal antibody YPF1 (Research Diagnostics,

Virulence Was reconstituted in BSL3 containment With

30
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select-agent security by introducing pCD2Ap by electropo
ration. Brie?y, 1’. peslis CO99-3015.S2 Was electroporated
With plasmid DNA from 1’. peslis CO99-3015.S6, that con

tained the 1’. peslis plasmids pFra (110 kb) and pPst (9 kb)
(Perry 1997) in addition to pCD2Ap. Their presence in the

40

transformation Would not pose a problem since the recipient

strains already contained copies of these tWo plasmids.
Transformed strains Were selected for Cb-resistance and

screened for the Pgm+ and Lcr+ phenotypes on agar media.
Individual isolates that passed these tests Were then subcul

ing 10 mM glutathione and collected in 1 mL aliquots. Purity
45

a third time into TMH With or Without 2.5 mM CaCl2 and
alloWed to groW for an additional tWo hours at 26° C. FolloW
50

Protection studies. Sets of 5 female outbred Swiss-Webster
mice Were immunized subcutaneously With 40 ug amounts of
55

tic acid to a ?nal concentration of 5%, and incubated over

6.25% vol/vol ?nal concentration) on days 0, 8, 14, and 22.
60

On day 35, they Were challenged intravenously With 10,000
CFU (5 LD50 doses) of Ypeszis CO99-3015.S7.
Similarly, groups of 8 C57BL/ 6 mice Were immunized

With 80 ug of HT-LcrV, GST-YadCl37_4O9, or GST (Sigma

Chemical Company, St. Louis, Mo.) adjuvanted With ALHY

ing to a culture OD620 of 2.0 and heated to 95° C. for 15
minutes. Half of each heat-treated sample Was plated and
incubated for 5 days at 28° C. to ensure that no viable cells

puri?ed fusion proteins (GST-YadCl37_4O9, or HT-LcrV) or
buffer emulsi?ed With ALHYDROGEL® (aluminum

hydroxide gel) (Sigma Chemical Company, St. Louis, Mo.;

night at 4° C. to precipitate secreted proteins. The rest of the
supernatant Was discarded. The precipitated proteins Were
collected by centrifugation at RT. Pellets of Whole cells and of

remained prior to removing the samples from the contain
ment facility.

in E. coli DHSO. from plasmid pHT-V and puri?ed on Talon

metal-a?inity resin (Clonetech Laboratories, Inc, Palo Alto,
Calif.) as described by Fields, 1999.

Cells Were pelleted in a microcentrifuge at room temperature

secreted proteins Were suspended in lysis loading buffer (400
mM TrisCl, pH 6.8, 25% glycerol, 8% SDS, 5% dithiothrei
tol, 0.4% bromophenol blue) to a concentration correspond

liant blue. Protein-containing fractions Were pooled and dia

lyzed, and the protein concentration measured by the bicin
choninic acid assay (Pierce Chemical Co., Rockford, 111.).
N-terminally His6-tagged LcrV (HT-LcrV) Was expressed

hours prior to the experiment. The cultures Were subcultured

(RT) for 10 min. The top 250 pl of supernatant Was removed,
transferred to a microcentrifuge tube containing trichloroace

Were harvested by centrifugation at 4° C., and resuspended at
0.05 the original volume in column buffer (20 mM Tris, 200
mM NaCl, 1 mM EDTA pH 7.4). Samples Were passed tWice
through a French press to lyse bacteria, cleared by centrifu
gation at 9000><g for 30 minutes at 4° C., diluted 1:4 With
column buffer and passed over a glutathione sepharose col
umn. Bound protein Was eluted using column buffer contain
Was assessed on SDS-PAGE gels stained With Coomasie bril

tured tWo times in 3 ml TMH+Cb at 26° C. for a total of 24

ing this, each culture Was shifted to 37° C. and permitted to
groW another four hours. A 500-111 sample of each culture Was
removed and brie?y placed on ice to aid cellular aggregation.

of 0.5, IPTG Was added to a ?nal concentration of 1 .0 mM and
the bacteria Were incubated for an additional 3 hours. Cells
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DROGEL® as in the previous experiment. TWo Weeks after
the 3rd immunization, the mice Were challenged intranasally
With 3000 CFU ofCO92.S2 (6 times the LD50 dose) in BSL3
conditions.
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Determination of IgG isotypes. Measurement of antibody
titer and isotype response Was performed by a modi?ed

arrangement seen inYadA, although the amino-acid sequence
similarity is not strong (FIG. 1). There is essentially no simi

ELISA on serum samples taken 1 Week prior to bacterial

larity betWeen YadA and the tWo predicted I’. peslis proteins

challenge. 96-Well ELISA plates Were coated With 10 ug/ml
of GST-YadCl37_4O9, HT-LcrV, GST or With buffer alone.

in the head regions.YadC is 25% identical and 45% similar in
285 amino acids in the C-terminus of YadA. yadC encodes a

Mouse sera Were then used at serial dilutions to a maximum

putative 622 amino acid preprotein While yadB encodes a

dilution of 115,120,000. HRP conjugates against mouse IgG,

putative 364 residue preprotein. The predicted YadC protein

IgG1, IgG2a, IgG2b, and IgG3 (BD Pharmingen, San Diego,

(61 .6 kDa) has a much larger head domain than doesYadB (35

Calif.) Were used as secondary antibodies. Protein-speci?c

kDa), Which carries only a short extension N-terminal to the
neck domain. The isoelectric point of YadC is 4.0 While
YadB’s PI is 4.5. BothYadB andYadC have signal sequences

antibody titer Was estimated as the maximum dilution of
serum giving an absorbance at 450 nm reading 0.1 units over

as found by SignalP 3.0 (Bendtsen 2004). These observa
tions, considered With the yadBC bicistronic genetic arrange
ment, suggest that YadB and YadC may function together.
Importance of YadC for virulence in bubonic plague.

the non-immunized mouse background sera (pre-immuniZa
tion sera). Mean titers Were determined per treatment group.

Human macrophages and cytokine analysis. The cytokine
response of human peripheral blood monocytes (PBMs) to
HT-LcrV, GST-YadCl37_4O9, and the negative control GST
Was evaluated. Blood Was obtained from tWo healthy volun

teers. Red blood cells Were lysed With ACK buffer (155 mM

NH4Cl/l mM KHCO3/0.5 mM EDTA, pH 7.2), the samples
Were Washed, and PBMs Were isolated by Ficoll-Paque den
sity gradient. PBMs Were cultured for one Week in RPMI With
12.5% human serum and 10 ug/ml of penicillin, streptomy
cin, and neomycin at a concentration of 1><106 cells/ml in 5%

20

CO2 to differentiate into macrophages.
Differentiated PBMs Were stimulated With 10 pg of F1,

Applicants have found that some human plague convalescent
sera recogniZe YadC, and a yadBC mutant 1’. peslis has been
found to shoW decreased adherence to epithelioid cells (For
man 2006), suggesting that YadB and YadC might have a
virulence role in plague. Further, the yadBC mutant Was
attenuated from the subcutaneous route (mimicking bubonic
plague) as compared to the virulent I’. peslis parent strain.
This ?nding shoWs that yadBC encodes a neW virulence
determinant for bubonic plague. This attenuation Was not

25

demonstrated When mice Were challenged intranasally (mim

HT-LcrV, GST, or GST-YadCl37_409 in 96-Well ELISA plates.

icking pneumonic plague).

100 pL of supernatant Was removed at 3 hours and then at 24

Protection studies. One goal of the studies described herein
is to obtain information useful for improving subunit plague

hours. Supernatants Were kept at —800 C. until processed for

cytokine analysis. All analyses Were done in triplicate in 2
different experiments. Cytokine levels Were measured by

30

Cytokine Bead Analysis (BDBiosciences) and evaluated by

or against bubonic and systemic plague due to an F1+ strain.

flow cytometry.

Since YadC Was determined to be a virulence factor for

bubonic plague and is detectable by antibody. it likely is

Results

yadC Operon and Predicted Properties of YadC. The
adhesinYadA of the enteropathogenic yersiniae is encoded by

displayed on the bacterial surface Where it Would be acces
35

the same Lcr plasmid that encodes LcrV. YadA contributes to

colonization through binding to extracellular matrix compo
nents such as ?bronectin, collagen, and laminin that in turn

are bound to [31 integrins (Tahir E Y 2001; Hudson 2005).
YadA belongs to a family of oligomeric coiled-coil (Oca)

treatment by identifying components that Will provide pro
tection against pneumonic plague due to an F1- Ypeslis strain

40

adhesins that are a subgroup of autotransporters composed of
trimers With short outer membrane-anchor domains. The tri

sible to antibody. Therefore, its role as a protective antigen
Was tested. TWo tests Were made for protective ef?cacy, using
different challenge strains and infection routes. Mice Were
immuniZed and challenged either intravenously or intrana
sally, as outlined above.
Negative-control mice received either ALHYDROGEL®
only or GST-ALHYDROGEL® immuniZation. HT-LcrV-im
muniZed mice Were used as the positive control. From an

meric character may provide increased avidity for tight adher

intravenous route, a test With SWiss-Webster mice challenged

ence (HoicZyk 2000; Cotter 2005). Each YadA monomer is
composed of an N-terminal head that contains a collagen

With 5 LD5O doses (10,000 CFU) of Ypeszis CO99-3015.S7
45

and contributes to stability of the complex, a stalk composed
of seven 15-mer units, a coiled-coil linker of tWo to three

7-mer units that is necessary for transport of the head, neck,
and stalk through the outer membrane, and a membrane

50

GST-YadCl37_409 C57BL/6 mice given 6 LD5O doses (3,000
CFU) of Ypeslis CO99-3015.S9 survived pneumonic plague.

55

and the HT-LcrV-immuniZed group Where 50% survived the
challenge (FIG. 3). There Was not a signi?cant difference in
survival betWeen mice immuniZed With GST-YadCl37_409 or
With HT-LcrV in either experiment; hoWever, there Was a

60

signi?cant difference betWeen results for both proteins When
compared to the GST- or ALHYDROGEL®-only negative
control groups. Accordingly, YadC appears to be protective
against F1- 1’. peslis from both intravenous and intranasal
routes. This test also supports the prediction that YadC is

anchor (HoicZyk 2000; Tahir EY 2001 ; RoggenkampA 2003;
Nummelin H 2004).

This is compared to the GST control group (0 surviving mice)

In I’. peslis, the yadA gene contains a frameshift mutation
that prevents the expression of a functional YadA protein. To

identify surface proteins of potential pathogenic importance
for I’. peslis, We examined the I’. peslis CO92 genome for

genes encoding proteins similar to YadA and identi?ed the
1869 by ORF YPO1388 that Was subsequently named yadC.
yadC is likely part of a bicistronic operon With the upstream

1095 by ORF encoding another protein With homology to
YadA and called yadB (YPO1387). yadBC is fairly isolated

accessible to antibody in vivo and is a true surface-localized

protein.

on the chromosome With the nearest gene upstream gene 300

IgG isotypes. Protein-speci?c IgG1, IgG2A, and IgG2B,

base pairs aWay and the nearest doWnstream gene 366 base

pairs aWay.
The yadB and yadC genes in the chromosome of I’. peslis
CO92 also encode members of the Oca family (denoted as
653a/b in ref (HoicZyk 2000)) and share the structural

revealed no protection for those immuniZed With buffer alone,

full protection for HT-LcrV-immuniZed mice, and partial pro
tection for GST-YadCl37_4O9-immuniZed mice (With 40% of
mice surviving) (FIG. 2). After intranasal challenge, 87% of

binding motif, a neck that serves as a platform for the head
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and IgG3 antibodies Were measured by ELISA in the sera of
the mice immuniZed With GST-ALHYDROGEL®, GST

YadCl37_409 or HT-LcrV. As has been reported, protection
With the F1 -LcrV antigen is associated With predominantly a
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Th2 IgG1 response (Williamson 1999). Likewise, in experi

in?ammatory response. Additional pro-in?ammatory cytok

ments described herein, mice immunized With HT-LcrV dem
onstrated
a
similar
IgG
isotype
distribution

additional innate immune cells such as natural killer cells to

ines fromAMs suggest thatYadC may play a role in recruiting

(IgG1>IgG2a~IgG2b~IgG3, p<0.005 When IgG1 compared
to other isotypes). Mice immunized WithYadC demonstrated
a

more

balanced

Th1/Th2

the lung environment.
5

response

Finally, as YadC has shoWn to be required for virulence
from a subcutaneous infection and is partially protective

(IgG1:IgG3>IgG2a>IgG2b, p<0.005 When IgG1 and IgG3

against pneumonic and systemic plague, it is believed that

compared to other isotypes). The total IgG titers to GST

YadC polypeptides can be included in useful compositions
for treating I’. Peslis infection.

YadCl37_409 (1 :5.6><106) Were signi?cantly higher than those

F1+ Subcutaneous Challenge and F1“ Intranasal Challenge

for HT-LcrV (1 :1><106) and total IgG titers to the GST com

ponent in the negative control mice (1:6.4><105).
Anti-in?ammatory/pro-in?ammatory cytokines.

of Subjects Treated With Composition Including Full-Length
YadC Polypeptide.

In

The folloWing is a prophetic example. Studies are con
ducted to determine Whether subjects treated With a compo

response to stimulation With either GST-YadCl37_4O9, HT
LcrV, or GST, PBMs produced little or no IL-10. PBMs
stimulated With YadC shoWed a signi?cant TNF-ot and IL-6
production that Was much higher than that due to LPS or

sition including the YadC polypeptide of SEQ ID NO: 1 are
protected from: subcutaneous challenge With 1’. Peslis C092

pCD2 Ap(res) F1", and intranasal challenge With 1’. Peslis
C092 pCD2 Ap(res) F1“.
For the study involving subcutaneous challenge, three

HT-LcrV (FIG. 4). IL-12 production Was not detectable in
response to either GST-YadCl37_409 or HT-LcrV (not shoWn)
but a small amount of IL-1 Was produced in response to

GST-YadCl37_409 but not to HT-LcrV. Overall, YadC pro

20

groups of mice are provided. A test group is immuniZed With

vided more of a pro-in?ammatory response than did LcrV

the composition including the YadC polypeptide of SEQ ID

(i.e., increased IL-1 and IL-6). This ?nding suggests that a

NO: 1, a positive control group is immuniZed With an HT

more balanced Th1/Th2 plague treatment composition is pos
sible. An experiment Was also conducted using human alveo

LcrV composition, and a negative control group receives
adjuvant alone (ALHYDROGEL®). I’. Peslis C099 F1+ cells
are plated on HIB agar plates containing 2.5 mM CaCl2,

lar macrophages (AM) from bronchoalveolar lavage ?uid.

25

0.10% xylose containing 50 ug/ml Cb (sHIBCZ750 agar), and
Congo Red containing 50 ug/ml Cb (Congo Redcbso). Pig

This test revealed a different cytokine pro?le With signi?
cantly more IL-10 produced in response to HT-LcrV than to

that GST-YadCl37_409 Was more pro-in?ammatory and HT

mentation (Pgm+) colonies are picked and placed into media.
The sample is then vortexed and the concentration is deter
mined by obtaining the 0D620 of a 1:20 dilution. Mice are
anesthetiZed, and subcutaneously challenged With about 100

LcrV Was anti-in?ammatory. These different cytokine pro

cells/100 ul ofC099 F1+Ypestis.

GST-YadCl37_409 and signi?cant IL-12 production after
stimulation With GST-YadC 137409 but not With HT-LcrV or

GST alone (data not shoWn). Again, the overall picture Was

30

?les suggest that the antigens presented during bubonic and

For the study involving intranasal challenge, three groups

pneumonic plague have a very different immune effect. These

of mice are provided. A test group is immuniZed With the

data, combined With the previous challenge experiments, pro

35

composition including the YadC polypeptide of SEQ ID NO:

vide evidence that surface proteins like YadC Would be ben
e?cial in inducing a more robust adaptive immunity response

composition, and a negative control group receives adjuvant

in future plague treatment compositions.
Discussion. It is clear from previous studies (CoWan 2000)

plated on HIB agar plates containing 2.5 mM CaCl2, 0.10%

that I’. peslis has multiple adhesins and invasins to substitute
for the absence of proteins such as YadA. These and other I’.
peslis surface proteins could alter the current plague treat

1, a positive control group is immuniZed With an HT-LcrV

alone (ALHYDROGEL®). I’. Peslis C099 F1+ cells are
40

(Pgm+) colonies are picked and placed into media. The
sample is then vortexed and the concentration is determined
by obtaining the 0D620 of a 1:20 dilution. Mice are anesthe

ment compositions to elicit a more balanced Th1/ Th2 pheno

typic pro?le. Antigens, such as those identi?ed herein, are
desirable for their ability to induce production of antibodies

xylose containing 50 ug/ml Cb (sHIBCl750 agar), and Congo
Red containing 50 ug/ml Cb (Congo Redcbso). Pigmentation

45

that can block crucial surface function such as epithelial

tiZed, and intranasally challenged With about 5000 cells/ 20 pl
ofC099 131-1’. peslis.

adhesion and invasion. Ideally, genes for such crucial proteins

For the HT-LcrV-treated mice receiving subcutaneous

could not be deleted from a potential bioterroristic Weapon

challenge, no symptoms are observed, and there is an overall

Without loss of virulence, unlike F1. This study examined 1’.
peslis YadC Which, as an acidic protein, could have a signi?
cant impact on the bacterial surface and be important in

ho st-patho gen interactions.
A critical step in the clearance of pulmonary infections is
the ability of the lung antigen-presenting cell to migrate to
regional lymph nodes Where it can present the antigen to T

survival of 100%. For the mice treated With adjuvant alone,
50

For YadC (SEQ ID N0:1)-treated mice receiving subcutane
ous challenge With C099 F1+I’. peslis, there is a protective

effect, as compared to the mice receiving adjuvant alone.
For the HT-LcrV-treated mice receiving intranasal chal
55

With adjuvant alone, after intranasal challenge, there are no
mice that survive. For YadC (SEQ ID N0:1)-treated mice

receiving intranasal challenge With C099 Fl‘I’. peslis, there
60

by a characteristic population of DCs (CD11c"DEC2053O
CD11b_) (Bosio C 2005). Data presented here suggest that
IL-1, TNF-ot, and IL-6 that Would favor development of adap
tive Th1 cellular immunity in the lung and increased local

is a protective effect, as compared to the mice receiving

adjuvant alone.

Was given to mice intratracheally, the bacteria Were taken up

PBMs When stimulated by a more favorable antigen (i.e.,
YadC) can participate in the induction of cytokines such as

lenge With C099 Fl'I’. peslis, no symptoms are observed,
and there is an overall survival of 100%. For the mice treated

cells to initiate an adaptive immune response. Previous stud
ies have demonstrated a role for macrophage-lineage cells in

mediating protection by anti-LcrV antibody in at least the
liver (Philipovskiy A V 2004; CoWan C 2005; Philipovskiy
2005). Recently it has been shoWn that When Lcr' I’. peslis

after subcutaneous challenge, there is a loW overall survival.
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SEQUENCE LISTING

<l60> NUMBER OF SEQ ID NOS:

3

<211> LENGTH: 622
<212> TYPE: PRT

<2l3> ORGANISM: Yersinia pestis
<4oo> SEQUENCE:

1

Met Asn Lys Glu Ile Lys Arg Met Gln Arg Met Gln Cys Ile Tyr Ile
1

5

1o

15

Ala Thr Trp Leu Ile Ala Val Phe Thr Ser Pro Ile Val Ile Ala Asn
2o

25

3o

Asn Thr Asn Ile Asn Gly Ser Thr Asn Asn Asn Gly Asn Gly Thr Ile
35

4o

45

Asn Ile Phe Asp Ala Ser Ser Asn Asn Asp Ile His Thr Leu Thr Gly
50

55

6O

Leu Gly Asn Glu Gln Leu Gly Gly Phe Ser Asn His Leu Ile Asp Ser
65

7o

75

80

His Asn Asn Thr Ile Asp Gly Gly Gln Ser Asn Asn Leu Val Ser Ser
85

9o

95

Asp Gly Asn Met Ile Ser Ala Ile Ser Leu Gly Asp Gly Leu Phe Tyr
100

105

110

Gly Ala Gln Asn Asn Thr Leu Ile Asn Ser Asn Asn Asn Leu Leu Ile
115
120
125

Val Thr Gln Gly Ser Thr Ile Ile Asp Ser Asp Ser Asn Thr Val Ser
130

135

140
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continued

Gly

Ile Ser Asn Asn Leu Ile Glu Ser Asn Ser Asn Ile Ile

145

150

Glu Asn Ser

Cys Tyr

Ser

Asp

165

Val

Asp

Pro Ala Ser Pro Ser
170

Asn Thr Leu Ile

Asn
180

Gly

Ala Leu Asn

Gly

Ser

Gly

Asp

Gly

Gly Gly Gly

His

Tyr

Asn Thr Ile Ser
230

Ser Glu Asn Asn Val Thr
245
Asn Asn

Tyr

Val Ile

Asp

Asp

Thr His Asn Asn Ile Ile Ala

Ser Thr

Asp

Asn Asn
235

Asn

Gly

Asn

Gly Gly

Gly

Ile

Ser

Gly Arg Asp Asp

Gly

Gly

Asn Met

Gly

Gly

Asn Asn Val Val Asn Ile
330

Gly

Ser

Gly

355
Asn Ile

Gly Asp Arg

Ser

Leu Thr

Gly

Val

Gly Asp

285

Ser Thr Leu Thr
310

Ile Ala Leu

Gly

270

Gly

Gly

Gly

255

280

Asn Asn Ser Ala Ser Leu
340

Gly

240

Ala Asn Ile Asn

Asn Ser Thr

325

Ile Phe

250

Asp Gly

Asn Ser Ile Leu
275

Thr Ser

Asp

265

305

Trp Cys

Asn Asn Thr Ile Thr
190

Ser Val Thr Ala Ile Thr Asn Ser Val Val Phe Gly
290
295
300

Gly

Ala

220

260

Glu

Gly

Asn
160

Leu His Asn Ser His Asn Asn Asp Ile Ile Ala
200
205

Ser Ser Val Asn Asn Leu Met
210
215

225

Asp

185

195

Gly

155

Thr

Asp

Gly

345

Asn Thr Ser

Ser Val Ser Val Ser Gly
315
320

Gly Gly

Ala Ala Asn
335

Ser Val Ser Ser Glu
350

Ser Ile Ala Thr
360

Gln Ile Thr Ser Val

Gly

Arg

Asn
365

Lys Lys Gly

Asp

Gly

Glu Leu

Val Glu Asn

380

Thr

Asp

Thr Ile Asn Val Ser Gln Leu Asn

385

390

Asp

Leu Asn Leu Ser Asn Glu
405

Tyr

Ser

Asp

Tyr

Thr

Asp

Ala Ser Leu

Glu Asn Ile Asn Asn
420

Gly

Ser Phe

Asp Asp

395

Val
400

Asn Ser Phe Ser Thr Val Thr
410
415

Asp

Thr Val Leu Asn

425

430

Glu

Tyr

Thr

Asp

Asn Ser Ile Leu Leu Val Thr Asn Glu
440
445

Ser Asn Asn
450

Tyr

Thr

Asp

Asn
455

Gly

Tyr

Ala

Asp

Glu Ser Leu Leu Ala Ile

Thr Thr

435

Asn Ile
465

Tyr
Tyr

Met Ser Asn Leu Ile
485

Tyr

495

Ser
515

Arg

Thr Phe

Leu Thr
530

Tyr

Ser Asn

Lys

Gln

Gln
545

Asp

Ile Asn Glu

Tyr

Gln

Arg

Thr

Phe

Gln Leu Asn Ala
550

Gln

Tyr

Lys

Asn Glu Phe

525

Gly Gly

Phe

535

Lys

Gly Lys
510

520

Gly Lys

Ala

Asn Glu Glu Ala
480

490

Tyr

Thr

Tyr

Val Thr Leu Asn Asn Ala Asn Asn

Leu Ser Val Asn Thr Ile Ile
500
505

Thr

Asp

Asp

Met Glu Ser Val Ser Asn
460

Asp Lys Asp

Ile Asn

540

Gly

Ile Ala Ala Thr Met Ala Ala
555

560
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—cont inued
Ala Val Ile Pro Gln Lys Ser Gly Ser Lys Val Ser Ile Gly Val Gly
565
Leu Ala

5'70

575

Gly Tyr Ser Asp Gln Gly Ala Gly Ser Val Gly Ala Ile Trp
580

585

590

Val Asn Gln Arg Ile Thr Met Asn Thr Thr Met Thr Tyr Asp Thr
595

Gln

600

Arg Gly Val Ser
610

Leu Leu
615

605

Thr Gly Leu Ser Ile Gly Ile
620

SEQ ID NO 2
LENGTH: 1869
TYPE: DNA

ORGANISM: Yersinia pestis
SEQUENCE: 2

atgaataagg aaattaaacg gatgcaacgg atgcaatgca tatatatcgc cacttggtta

60

atcgcagtat ttacttcgcc gatagtgata gctaacaata cgaatattaa tggcagtacc

120

aataataacg gtaatggtac

tttgacgcca gcagtaataa cgatattcat

180

acactaaccg gtcttggtaa tgagcagttg ggaggattta gtaatcatct tatcgactct

240

cgatagacgg tggtcagagt aacaacctgg taagtagcga tggcaatatg

300

atcagcgcca ttagcttggg cgatggcctc ttctacggcg cgcagaataa cacgttaata

360

aactcaaaca acaacctact

tattgtcact cagggcagta ctataataga ttctgatagt

420

aatactgtgt ctggcattag

taataatctt

atagagagca acagcaatat tatcggtaat

480

gaaaatagtt gttattcgga tcccgcgtcc ccatcaggag cgtggtgcgt tgacaatcaa

540

aatacgctca ttggcagtga taacaatacg atcactggtg cgctgaatgg

tcttcacaac

600

agtcataaca atgatattat tgctagctct gtaaataatt taatggatac gcataataat

660

attatcgcgg gagggcacta

51911991199119 gaaacaatga catttttggg

720

agtgaaaaca atgttactga cagcaccgac gccaatatca atggtagtaa taactacgtg

780

atagatggga atggaattgg tcgagatgat ttgactgaag

attgggcggc

840

ggattcagta accgcgatta ccaatagcgt ggtgttcggc

900

ggtaatacat ctggtaattc aaccggctcc actctgacag attctgtatc ggttagcggc

960

aacggtacat cggggaataa tgtcgttaat atcggcggag cggcaaacgg taataatagt

1020

gctagcttag gtacaggctc ggtatcctct gaaggaggaa ttgcattggg tagcggttcg

1080

attgctacac ggaatgatga actgaatatc ggtgatagac aaattaccag cgttaaaaaa

1140

ggtgttgaga atacagatac aatcaatgtt agtcagttaa acgatagctt tgatgatgtt

1200

ctgaatttat caaatgaata ttctgacaac

aaatataaat

1260

aattatactg atgcctcatt agatactgtg ttgaatacaa ctggtgaata taccgacaac

1320

tcaatattat

tggttactaa tgaaagcaat aattatactg acaatggcat ggagagtgtt

1380

agtaattatg

caaatatcta

tgctgatgaa tctttgttag

ctatctataa

tgaagaggct

1440

aattacatgt

ctaatcttat

agatgtgacg ttaaataatg

ctaataacta

tactgatctt

1500

tcagttaata

ccattatata

taccggaaaa caatatacag actctcgaat caatgagtac

1560

tattctaatg gaaaatttgg cggttttgat

1620

aaagatatta atcaaaagca gaaacaatta aacgcgggaa tagcggcgac gatggctgct

1680

gcggttattc

gggttctaaa gtctctattg gtgtcgggct tgcaggatat

1740

agcgatcaag gcgcaggatc tgtgggagcg atttggcatg taaatcaacg aatcacaatg

1800

cataataata

tctggcaata

caacgtactt ttaaaaatga

ctcaaaaatc

aatcaatatt

caacaccatt

atttttaacc

tctttttcca

ataactctat

ctgtcactga
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—cont inued

aatacaacga tgacttacga tactcaacgt ggtgttagtt tattaacggg tttatctatc

1860

ggcatatga

1869

<2lO> SEQ ID NO 3
<2l2> TYPE:

PRT

<2l3> ORGANISM: Yersinia pestis
<400> SEQUENCE: 3

Asp Ser Asp Ser Asn Thr Val Ser Gly Ile Ser Asn Asn Leu Ile Glu
1

5

1O

15

Ser Asn Ser Asn Ile Ile Gly Asn Glu Asn Ser Cys Tyr Ser Asp Pro
20

25

3O

Ala Ser Pro Ser Gly Ala Trp Cys Val Asp Asn Gln Asn Thr Leu Ile
35

4O

45

Gly Ser Asp Asn Asn Thr Ile Thr Gly Ala Leu Asn Gly Leu His Asn
5O

55

6O

Ser His Asn Asn Asp Ile Ile Ala Ser Ser Val Asn Asn Leu Met Asp
65

7O

75

8O

Thr His Asn Asn Ile Ile Ala Gly Gly His Tyr Asn Thr Ile Ser Gly
85

9O

95

Gly Gly Asn Asn Asp Ile Phe Gly Ser Glu Asn Asn Val Thr Asp Ser
100

105

110

Thr Asp Ala Asn Ile Asn Gly Ser Asn Asn Tyr Val Ile Asp Gly Asn
115

120

125

Gly Ile Gly Arg Asp Asp Leu Thr Glu Asp Asn Ser Ile Leu Gly Gly
130

135

140

Ser Gly Asn Met Gly Val Gly Asp Ser Val Thr Ala Ile Thr Asn Ser
145

150

155

160

Val Val Phe Gly Gly Asn Thr Ser Gly Asn Ser Thr Gly Ser Thr Leu
165

170

175

Thr Asp Ser Val Ser Val Ser Gly Asn Gly Thr Ser Gly Asn Asn Val
180

185

190

Val Asn Ile Gly Gly Ala Ala Asn Gly Asn Asn Ser Ala Ser Leu Gly
195

200

205

Thr Gly Ser Val Ser Ser Glu Gly Gly Ile Ala Leu Gly Ser Gly Ser
210

215

220

Ile Ala Thr Arg Asn Asp Glu Leu Asn Ile Gly Asp Arg Gln Ile Thr
225

230

235

240

Ser Val Lys Lys Gly Val Glu Asn Thr Asp Thr Ile Asn Val Ser Gln
245

250

255

Leu Asn Asp Ser Phe Asp Asp Val Leu Asn Leu Ser Asn Glu Tyr Ser
260

Asp

265

270

US 7,815,911 B1
27
What is claimed is:
1. A composition for inducing an immune response in a

subject, comprising a fusion protein including GST and
amino acid residues 137-409 ofYadC (SEQ ID NO: 3).
2. The composition of claim 1, Wherein the composition
induces an immune response against Fl-positive and

Fl-negative strains of 1’. peslis.
3. The composition of claim 1, Wherein the composition
induces an immune response against E 1 -negatiVe strains of 1’.

peslis.
4. A method of inducing an immune response in a subject,

comprising: introducing into the subject a composition of

28
7. The method of claim 4, Wherein the subject is in need of
treatment for a 1’. peslis infection.

8. The method of claim 4, Wherein the subject is susceptible
to 1’. peslis infection.
9. A composition for inducing an immune response in a

subject, comprising: a fusion protein comprising: a fragment
of the YadC polypeptide consisting of amino acid residues
137-409 ofYadC (SEQ ID NO: 3); and additional amino acids
at the N-terminal and/or C-terminal end of the fragment (SEQ
ID NO: 3) that differ from those amino acids present in the

YadC polypeptide (SEQ ID NO: 1).
10. A composition for inducing an immune response in a

claim 1.

5. The method of claim 4, Wherein the composition induces
an immune response against Fl-positive and Fl-negative
strains of 1’. peslis.
6. The method of claim 4, Wherein the composition induces
an immune response against Fl-negative strains of 1’. peslis.

subject, comprising: an isolated polypeptide molecule con
sisting of amino acid residues 137-409 ofYadC (SEQ ID NO:

3).

